Generic Ekterly Availability
Last updated on Aug 6, 2025.
Ekterly is a brand name of sebetralstat, approved by the FDA in the following formulation(s):
EKTERLY (sebetralstat - tablet;oral)
-
Manufacturer: KALVISTA
Approval date: July 3, 2025
Strength(s): 300MG [RLD]
Is there a generic version of Ekterly available?
No. There is currently no therapeutically equivalent version of Ekterly available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ekterly. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors
Patent 10,364,238
Issued: July 30, 2019
Inventor(s): Davie; Rebecca Louise et al.
Assignee(s): Kalvista Pharmaceuticals Limited (Porton Down, Wiltshire, GB)The present invention provides compounds of formula (I): (I) compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B, W, X, Y and Z are as defined herein. ##STR00001##
Patent expiration dates:
- November 26, 2035✓✓
- November 26, 2035
-
N-((het)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors
Patent 10,611,758
Issued: April 7, 2020
Inventor(s): Davie; Rebecca Louise et al.
Assignee(s): Kalvista Pharmaceuticals Limited (Porton Down, Wiltshire, GB)The present invention provides compounds of formula (I): ##STR00001##
compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B, W, X, Y and Z are as defined herein.Patent expiration dates:
- November 26, 2035✓
- November 26, 2035
-
N-((HET)arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors
Patent 11,001,578
Issued: May 11, 2021
Inventor(s): Davie; Rebecca Louise et al.
Assignee(s): KALVISTA PHARMACEUTICALS LIMITED (Wiltshire, GB)The present invention provides compounds of formula (I): ##STR00001##
compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B, W, X, Y and Z are as defined herein.Patent expiration dates:
- November 26, 2035✓✓
- November 26, 2035
-
N-((HET)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors
Patent 11,084,809
Issued: August 10, 2021
Inventor(s): Davie; Rebecca Louise et al.
Assignee(s): KalVista Pharmaceuticals Limited (Porton Down, GB)The present invention provides compounds of formula (I): ##STR00001##
compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B, W, X, Y and Z are as defined herein.Patent expiration dates:
- November 26, 2035✓✓✓
- November 26, 2035
-
N-((het)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors
Patent 11,198,691
Issued: December 14, 2021
Inventor(s): Davie; Rebecca Louise et al.
Assignee(s): KalVista Pharmaceuticals Limited (Porton Down, GB)The present invention provides compounds of formula (I): ##STR00001##
compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B, W, X, Y and Z are as defined herein.Patent expiration dates:
- November 26, 2035✓
- November 26, 2035
-
Polymorphs of n-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[2-oxopyridin-1-yl)methyl]phenyl} methyl)pyrazole-4-carboxamide as iallikrein inhibitors
Patent 11,230,537
Issued: January 25, 2022
Inventor(s): Beaton; Haydn et al.
Assignee(s): KalVista Pharmaceuticals Limited (Porton Down, GB)The invention provides new polymorphs of N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide and salts thereof, pharmaceutical compositions containing them and their use as kallikrein inhibitors in therapy. ##STR00001##
Patent expiration dates:
- December 25, 2037✓✓
- December 25, 2037
-
Dosage forms comprising a plasma kallikrein inhibitor
Patent 11,234,939
Issued: February 1, 2022
Inventor(s): Collett; John Herman et al.
Assignee(s): KalVista Pharmaceuticals Limited (Porton Down, GB)The present invention relates to oral solid dosage forms comprising a plasma kallikrein inhibitor, in particular a solid form (Form 1) of the compound of Formula A. Also provided are methods of preparing oral solid dosage forms comprising the compound of Formula A using Form 1 of the compound of Formula A.
Patent expiration dates:
- January 26, 2039✓✓
- January 26, 2039
-
Polymorphs of N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide and salts thereof
Patent 11,739,068
Issued: August 29, 2023
Inventor(s): Beaton; Haydn et al.
Assignee(s): KalVista Pharmaceuticals Limited (Porton Down, GB)The invention provides new polymorphs of N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3 -(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide and salts thereof, pharmaceutical compositions containing them and their use in therapy.
Patent expiration dates:
- June 23, 2037✓
- June 23, 2037
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- July 3, 2030 - NEW CHEMICAL ENTITY
More about Ekterly (sebetralstat)
Patient resources
Professional resources
Related treatment guides
Related/similar drugs
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
